Evacetrapib
Evacetrapib suppresses colorectal cancer cell growth by blocking Wnt/beta-catenin signaling and activating JNK (Biol Pharm Bull 2022)
Original title: Evacetrapib Elicits Antitumor Effects on Colorectal Cancer by Inhibiting the Wnt/β-Catenin Signaling Pathway and Activating the JNK Signaling Pathway
With no effective options remaining for many advanced colorectal cancer patients who progress after chemotherapy, targeted therapy, and immunotherapy, new drugs are urgently needed. Since CETP has been implicated in tumor development and proposed as a possible colorectal cancer therapeutic target, this study tested the CETP inhibitor evacetrapib against colorectal cancer cells. Evacetrapib suppressed colorectal cancer cell growth by inhibiting the Wnt/beta-catenin signaling pathway while simultaneously activating the c-Jun NH2-terminal kinase (JNK) signaling pathway, demonstrating an anticancer effect through these two mechanisms and identifying evacetrapib as a possible option for treating colorectal cancer.
Original abstract
Despite advances in colorectal cancer (CRC) treatment, most advanced CRC patients who experience disease progression after chemotherapy, targeted therapy, and immunotherapy face a situation in which there is no available medicine. Thus, new therapeutic drugs for CRC are urgently needed. Studies have shown that cholesteryl ester transfer protein (CETP) has a vital role in tumor development and is a possible target for CRC therapy. We found that Evacetrapib, a CETP inhibitor, suppressed CRC cell growth by inhibiting the Wnt/β-catenin signaling pathway and activating the c-Jun NH2-terminal kinase (JNK) signaling pathway in CRC. Therefore, Evacetrapib displays an anti-cancer effect and is a possible option for treating CRC.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.